MARKET

PRNB

PRNB

Principia Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

57.55
-0.83
-1.42%
Opening 12:30 07/02 EDT
OPEN
59.24
PREV CLOSE
58.38
HIGH
59.24
LOW
56.91
VOLUME
42.89K
TURNOVER
--
52 WEEK HIGH
75.65
52 WEEK LOW
25.35
MARKET CAP
1.90B
P/E (TTM)
-23.6462
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PRNB stock price target is 78.57 with a high estimate of 97.00 and a low estimate of 72.00.

EPS

PRNB News

More
Principia Announces First Patient Enrolled in Sanofi's Phase 3 Trial of SAR442168 in Relapsing MS
Principia Biopharma Inc. (NASDAQ: PRNB) today announced that the first patient has been enrolled in its partner Sanofi's Phase 3 clinical trial of SAR442168 in patients with relapsing multiple sclerosis (RMS). Upon dosing, Principia will be entitled to a $
Benzinga · 06/23 09:46
Principia Announces First Patient Enrolled in Sanofis Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis
GlobeNewswire · 06/23 06:15
Hedge Funds Have Never Been This Bullish On Principia Biopharma Inc. (PRNB)
Insider Monkey · 06/18 20:07
Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus
GlobeNewswire · 06/12 21:05
Principia's rilzabrutinib shows positive effect in rare skin-blistering disorder
Seeking Alpha - Article · 06/12 20:26
Principia Announces Data From Phase 2 Part B Trial In Pemphigus
Clear dose-response combined with decreased daily corticosteroid usage Response rate increased with extended duration of treatment to six months while maintaining a favorable safety profile SOUTH SAN FRANCISCO, Calif.,
Benzinga · 06/12 20:05
Principia's rilzabrutinib shows positive response in immune thrombocytopenia
Seeking Alpha - Article · 06/12 13:43
Principia Biopharma Highlights Presentation Of Updated Positive Data Of Rilzabrutinib For Immune Thrombocytopenia In Ongoing Phase 1/2 Trial
Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced positive data on durability of response from an ongoing Phase
Benzinga · 06/12 10:10

Industry

Biotechnology & Medical Research
+1.04%
Pharmaceuticals & Medical Research
+0.71%

Hot Stocks

Symbol
Price
%Change

About PRNB

Principia Biopharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies to patients with unmet medical needs in immunology and oncology. It uses its Tailored Covalency platform to design and develop reversible covalent and irreversible covalent, small molecule inhibitors. Its pipeline includes PRN1008, PRN1371 and PRN2246. PRN1008 drug candidate is designed for the treatment of chronic immunological disorders. PRN2246 is an irreversible covalent BTK inhibitor for the treatment of multiple sclerosis (MS), and other central nervous system (CNS) diseases. PRN1008 is also being developed for the treatment of multiple autoimmune diseases, such as pemphigus. PRN1371 is an inhibitor of Fibroblast Growth Factor Receptor (FGFR), designed for the treatment of solid tumors. The Company also focuses on developing oral immunoproteasome inhibitor for the treatment of inflammation and autoimmune disorders.
More

Webull offers kinds of Principia Biopharma Inc stock information, including NASDAQ:PRNB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRNB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRNB stock methods without spending real money on the virtual paper trading platform.